Hutchinson I V, Bonavida B
Cancer Immunol Immunother. 1982;13(3):176-81. doi: 10.1007/BF00205384.
The role of antigen-reactive cell opsonization (ARCO) in a syngeneic tumor system and its effect on tumor progression was investigated. Thus, anti-tumor reactive T cells were prepared in vivo by immunization of normal SJL/J mice with mitomycin C-inactivated tumor cells of the syngeneic transplantable reticulum cell sarcoma (RCS) line LA-6. Dividing cells were subsequently labeled by injecting iodo-2-deoxyuridine (IUdR) into the same animals 3 days later. Antigen-reactive cells (*ARC) present in the radiolabeled, nylon wool-fractionated spleen cell population taken from these mice on day 4 and injected IV into syngeneic SJL/J mice bearing LA-6 tumors were diverted to the liver and away from the spleen. The effect was maximal by 8 days following inoculation of tumor cells, and was specific inasmuch as IUdR-labeled cells prepared by immunization with allogeneic spleen or tumor cells which were not opsonized in day-8 LA-6 tumor-bearing mice. Opsonization of *ARC in day-8 LA-6 tumor-bearing mice was completely abrogated by either prior injection of heat-aggregated immunoglobulin into the mice or preincubation of the *ARC in solubilized tumor antigen before injection into tumor-bearing mice, demonstrating the involvement of Fc receptors in the host and antigen-specific receptors on the *ARC, respectively, in the opsonizing process. When anti-LA-6 reactive T cells were incubated in serum from LA-6 tumor-bearing mice and then injected IV into normal syngeneic SJL/J mice, a similar liver diversion was observed. Serum from cyclophosphamide-pretreated mice injected with LA-6 or serum from mice given mitomycin C-inactivated LA-6 cells did not cause opsonization of tumor-reactive T cells, while a mixture of these two sera did have some *ARC opsonizing activity. Further experiments with SJL/J mice bearing spontaneous RCS tumor indicate that tumor-reactive T cells are also opsonized in these mice. The above studies and others suggested that ARCO may play an important role in vivo in the survival of tumors.
研究了抗原反应性细胞调理作用(ARCO)在同基因肿瘤系统中的作用及其对肿瘤进展的影响。因此,通过用丝裂霉素C灭活的同基因可移植网状细胞肉瘤(RCS)系LA-6的肿瘤细胞免疫正常SJL/J小鼠,在体内制备抗肿瘤反应性T细胞。3天后,通过向同一动物注射碘代-2-脱氧尿苷(IUdR)对分裂细胞进行标记。在第4天从这些小鼠采集经放射性标记、尼龙毛分离的脾细胞群体中的抗原反应性细胞(ARC),静脉注射到携带LA-6肿瘤的同基因SJL/J小鼠体内后,这些细胞被转移至肝脏而远离脾脏。接种肿瘤细胞后8天,这种作用达到最大,且具有特异性,因为用同种异体脾或肿瘤细胞免疫制备的IUdR标记细胞在第8天的LA-6荷瘤小鼠中未被调理。预先向小鼠注射热聚集免疫球蛋白或在将ARC注射到荷瘤小鼠体内之前在可溶性肿瘤抗原中进行预孵育,均可完全消除第8天LA-6荷瘤小鼠中ARC的调理作用,这分别证明了宿主中的Fc受体和ARC上的抗原特异性受体参与了调理过程。当抗LA-6反应性T细胞在LA-6荷瘤小鼠的血清中孵育,然后静脉注射到正常同基因SJL/J小鼠体内时,观察到类似的肝脏转移现象。注射LA-6的环磷酰胺预处理小鼠的血清或注射丝裂霉素C灭活的LA-6细胞的小鼠的血清均未导致肿瘤反应性T细胞的调理作用,而这两种血清的混合物确实具有一定的*ARC调理活性。对患有自发性RCS肿瘤的SJL/J小鼠进行的进一步实验表明,这些小鼠中的肿瘤反应性T细胞也会被调理。上述研究及其他研究表明,ARCO可能在体内肿瘤存活中发挥重要作用。